Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)

Farnie, Gillian; Johnson, R.J.; Williams, Kathryn Williams; Clarke, Robert B.; Bundred, Nigel

doi:10.4161/cc.27201

Cited by 19 publications

(17 citation statements)

References 34 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, HSC3, HSC4 and Ca9-22 cells were lapatinib-sensitive, and KB, SAS and DU145 cells were lapatinib-resistant. Previous studies reported that lapatinib reduced the formation of atmospheres and proliferation of the progenitor/stem-enriched ductal carcinoma in situ population regardless of the ErbB2 status [40] . Analyzing the sphere formation capacities of these cell lines.…”

Section: Proliferation Of Oscc Cell Lines In Floating Culturementioning

confidence: 93%

Molecularly-targeted therapy for the oral cancer stem cells

Ohnishi

Yasui

Nozaki

et al. 2018

Japanese Dental Science Review

View full text Add to dashboard Cite

SummaryHuman cancer tissues are heterogeneous in nature and become differentiated during expansion of cancer stem cells (CSCs). CSCs initiate tumorigenesis, and are involved in tumor recurrence and metastasis. Furthermore, data show that CSCs are highly resistant to anticancer drugs. Cetuximab, a specific anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is used in cancer treatment. Although development of resistance to cetuximab is well recognized, the underlying mechanisms remain unclear. Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR)/ErbB2, has antiproliferative effects and is used to treat patients with ErbB2-positive metastatic breast cancer. In this review, cetuximab and lapatinib-resistant oral squamous cell carcinoma (OSCC) cells proliferation and migration signal transduction passway is discussed by introducing our research.

show abstract

Section: Proliferation Of Oscc Cell Lines In Floating Culturementioning

confidence: 93%

Molecularly-targeted therapy for the oral cancer stem cells

Ohnishi

Yasui

Nozaki

et al. 2018

Japanese Dental Science Review

View full text Add to dashboard Cite

show abstract

“…We have published evidence of a cancer stem/progenitor population within human primary DCIS and DCIS cell lines using the in vitro mammosphere technique to enrich for tumor‐initiating cells and measure stem/progenitor activity . In patient samples we show that the number of mammospheres is significantly increased in high grade, poor prognosis DCIS, demonstrating increased cancer stem cell (CSC) activity .…”

Section: Introductionmentioning

confidence: 92%

Focal Adhesion Kinase and Wnt Signaling Regulate Human Ductal Carcinoma In Situ Stem Cell Activity and Response to Radiotherapy

et al. 2015

Self Cite

View full text Add to dashboard Cite

Cancer stem cells (CSCs) can avoid or efficiently repair DNA damage from radio and chemotherapy, which suggests they play a role in disease recurrence. Twenty percentage of patients treated with surgery and radiotherapy for ductal carcinoma in situ (DCIS) of the breast recur and our previous data show that high grade DCIS have increased numbers of CSCs. Here, we investigate the role of focal adhesion kinase (FAK) and Wnt pathways in DCIS stem cells and their capacity to survive irradiation. Using DCIS cell lines and patient samples, we demonstrate that CSC-enriched populations are relatively radioresistant and possess high FAK activity. Immunohistochemical studies of active FAK in DCIS tissue show high expression was associated with a shorter median time to recurrence. Treatment with a FAK inhibitor or FAK siRNA in nonadherent and three-dimensional matrigel culture reduced mammosphere formation, and potentiated the effect of 2 Gy irradiation. Moreover, inhibition of FAK in vitro and in vivo decreased selfrenewal capacity, levels of Wnt3a and B-Catenin revealing a novel FAK-Wnt axis regulating DCIS stem cell activity. Overall, these data establish that the FAK-Wnt axis is a promising target to eradicate self-renewal capacity and progression of human breast cancers. STEM CELLS

show abstract

“…Lapatinib was shown to not reduce self-renewal in the CSCs but inhibited their proliferation regardless of their HER2 status. These important studies indicate that lapatinib can lower DCIC CSC activity and suggest that lapatinib has potential therapeutic usefulness in preventing recurrence and progression of DCIC to invasive disease [288]. The efficiency of Herceptin is dependent on its ability to target HER2 in HER2-driven CSCs.…”

Section: Hotairm1mentioning

confidence: 99%

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Steelman¹,

Fitzgerald²,

Lertpiriyapong³

et al. 2016

CPD

View full text Add to dashboard Cite

The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.

show abstract

Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)

Cited by 19 publications

References 34 publications

Molecularly-targeted therapy for the oral cancer stem cells

Molecularly-targeted therapy for the oral cancer stem cells

Focal Adhesion Kinase and Wnt Signaling Regulate Human Ductal Carcinoma In Situ Stem Cell Activity and Response to Radiotherapy

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Contact Info

Product

Resources

About